Aldeyra Therapeu SEC Filings

Aldeyra Therapeutics reported Q3 2025 results with a net loss of $7,688,341, reflecting lower operating expenses year over year. Research and development expense was $5,430,757 (down from $12,441,509), and general and administrative expense was $2,570,375 (down from $3,696,067). Total other income, net, was $312,791, driven by interest income of $788,694 and interest expense of $475,903.

Liquidity and balance sheet: Cash and cash equivalents were $59,340,599 and marketable securities were $15,956,740 as of September 30, 2025. Total assets were $77,801,012 and stockholders’ equity was $49,244,543. Current portion of debt was $15,199,265, with the Hercules facility maturing on April 1, 2026 and interest‑only payments through that date under the amendment. The company stated its cash, cash equivalents, and marketable securities are expected to fund operations for at least the next 12 months.

Strategic items: Deferred collaboration revenue remained $6,000,000 related to the AbbVie option; as of November 5, 2025, AbbVie had not exercised the option. Under its $75.0 million at‑the‑market program, no shares were sold as of quarter end.

Aldeyra Therapeutics (ALDX) furnished an 8-K noting it issued a press release announcing positive Phase 2 results in alcohol-associated hepatitis, the prioritization of its RASP modulator product candidates, and an updated pipeline.

The company also reported an extension of its projected operational cash runway into the second half of 2027. The press release is included as Exhibit 99.1.

Aldeyra Therapeutics officer and director Michael Alfieri reported a non-derivative purchase of 2,500 shares of Aldeyra common stock on 08/13/2025 at a reported price of $5.30 per share. Following the transaction he beneficially owns 2,500 shares directly. The Form 4 was signed on 08/15/2025.

Perceptive Advisors and affiliated parties report a 6.8% stake in Aldeyra Therapeutics (ALDX), representing 4,051,631 shares. The filing states the Master Fund directly holds the shares, with Perceptive Advisors as investment manager and Joseph Edelman as managing member, each deemed to beneficially own the shares. All reported shares reflect shared voting and dispositive power (no sole power). The ownership percentage is calculated using 59,895,588 outstanding shares of common stock as reported by the issuer. The filers certify the holdings were not acquired to influence control.

Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics (ALDX), reported the sale of 22,073 shares of common stock on 08/11/2025. The disposals were executed to cover tax withholding obligations upon settlement of time-based restricted stock units. The sales produced a weighted average price of $5.1517, with individual trade prices in the range of $5.06 to $5.29. After the reported transactions the reporting person beneficially owned 221,799 shares, which includes 7,101 shares acquired under the company’s Employee Stock Purchase Plan. No derivative securities were reported.

Aldeyra Therapeutics (ALDX) Form 144 reports a proposed sale of 22,074 shares of common stock through Morgan Stanley Smith Barney on Nasdaq, with an aggregate market value of $116,109.24 and an approximate sale date of 08/12/2025. The filing states the shares were acquired as a Restricted Stock Unit grant on 07/15/2022 (46,401 units acquired) and that the consideration for the original acquisition was services rendered. The filer reports nothing to report for securities sold in the past three months.

The notice includes the seller's representation that they are not aware of any undisclosed material adverse information regarding the issuer.

Aldeyra Therapeutics (ALDX) Q2-25 10-Q shows the clinical-stage biotech remains pre-revenue but reduced operating losses.

• Net loss narrowed to $9.8 m (-42% YoY) on R&D cut to $8.5 m (-43%) and G&A cut to $1.7 m (-45%). Six-month loss fell to $19.7 m (-21%).
• Cash resources: $41.2 m cash & cash equivalents plus $40.7 m marketable securities = $81.9 m, funding “at least the next 12 months.” Cash burn H1-25 was $21.0 m vs $23.2 m prior year.
• Balance sheet shifts: Current liabilities rose to $29.5 m driven by term-loan re-classification (current portion $15.1 m) after interest-only period was extended to Apr-26; long-term debt now zero.
• AbbVie option: $6 m non-refundable fees remain deferred; AbbVie has not exercised the option to co-develop reproxalap and window now only 10 business days post-FDA decision.
• No commercial revenue; accumulated deficit reached $469.8 m.

Management believes existing liquidity plus interest income ($1.9 m YTD) cover operations for 12 months but acknowledges need for additional financing to advance late-stage assets reproxalap (dry eye) and ADX-2191 (retinitis pigmentosa) and to repay the $15.3 m Hercules facility at maturity in 2026.

Aldeyra Therapeutics (NASDAQ:ALDX) filed a Form 8-K reporting receipt of a Special Protocol Assessment (SPA) agreement letter from the FDA covering the pivotal trial design for ADX-2191, its investigational treatment for primary vitreoretinal lymphoma (PVRL). The SPA signals FDA concurrence that the study’s endpoints and analysis, if achieved, are sufficient for a future New Drug Application, materially reducing regulatory risk and potentially accelerating review. The related press release is furnished as Exhibit 99.1 under Item 7.01, with the same event noted under Item 8.01. No financial data, guidance, or operational changes were disclosed.